openPR Logo
Press release

Appointment of LITMUS Molecular Design President

07-03-2007 04:05 PM CET | Science & Education

Press release from: LITMUS LLC

/ PR Agency: Abchurch
LITMUS LLC, a leading global technology innovations company, today announces that Dr. Bill W. Massey has been appointed as President of its wholly owned subsidiary, LITMUS Molecular Design (“LMD”).

LMD is dedicated to the discovery and development of new molecular entities for the pharmaceutical, chemical and materials science industries. LMD’s technology dramatically improves the efficiency and predictive accuracy of the discovery and development process thereby substantially reducing the associated time and costs. Consequently LMD is able to generate significant value for users of its technology in their commercialization of new molecular entities.

LMD creates new molecular entities designed to have specified desired properties and characterizes the activity of existing molecules through the use of LITMUS Spectral Modeling, the application of its patented, cutting edge methodology called Spectral Data Activity Relationship (SDAR). The method uses computer modeling techniques to predict the properties that a molecular structure will exhibit based solely on spectral analysis (LITMUS Spectral Modeling). This removes the need to physically create the molecule and exhaustively test for which individual properties it possesses. LMD can also screen existing molecules for desirable, or undesirable, activity. As all of these capabilities are assessed in silico (on the computer), the time and cost are greatly reduced. Developed by scientists at the U.S. Food and Drug Administration (FDA)’s National Center for Toxicological Research, LITMUS Spectral Modeling can predict a wide range of a given molecular structure’s scientifically important properties, including chemical reactivity, carcinogenicity, biological activity, receptor-binding affinity, toxicity, metabolism, absorption, and chemical and physical properties. LMD owns the worldwide license on LITMUS Spectral Modeling.

LMD offers both products and services to its customers. LITMUS Molecular Entity Design (“L-MED”) is focused on creation of new chemical entities with specific biological activity, while LITMUS Molecular Analysis Services (“L-MAS”) is focused on the development of custom predictive models of biological activity.

Dr. Massey has had a successful 15 year career in the pharmaceutical industry, spanning a variety of areas including pre-clinical research, clinical research, regulatory affairs, marketing, and business operations/planning. He has held senior management positions at Astra Merck Inc., Quintiles Central Nervous System (CNS) Therapeutics Inc., Scirex Corporation, and AstraZeneca plc. He has actively managed the preparation and submission of a number of original investigational new drug and product marketing applications, and has leadership experience in international drug development programs in the cardiovascular and CNS therapeutic areas. Dr. Massey received his PhD from the Department of Pharmacology and Interdisciplinary Toxicology of the University of Arkansas for Medical Sciences. He currently holds two adjunct faculty appointments in pharmacology, at the University of Arkansas for Medical Sciences, and psychiatry, at the University of Mississippi Medical Center, where he lectures on the pharmacology of anti-psychotics and antidepressants, and on development of drugs for neurological and psychiatric diseases.

Mark Diggs, Chief Executive Officer of LITMUS, commented: “This is a significant milestone in the development of LITMUS Molecular Design. With Dr. Massey’s appointment, LMD becomes fully operational and LITMUS Spectral Modeling will now be commercially available to the pharmaceutical, chemical, and materials sciences industries.”

Founded in 2002, LITMUS, LLC is headquartered in Little Rock, Arkansas USA, and has offices across America and in London, England. For more information, visit www.litmusgti.com.

LITMUS LLC
9821 Katy Freeway
Suite 500
Houston
Texas 77024
USA

Mark Diggs, Chief Executive Officer
Tel: 1 713 464 7770
mdiggs@litmusgti.com

For media enquiries:
Abchurch
Gareth Mead
Tel: 44 (0) 20 7398 7700
gareth.mead@abchurch-group.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Appointment of LITMUS Molecular Design President here

News-ID: 23411 • Views: 1634

More Releases from LITMUS LLC

Second Exclusive Cooperative Research Agreement with US Naval Air Warfare Center …
LITMUS, LLC, a leading global technology innovations company, today announces that its majority owned subsidiary, LITMUS Defense, LLC, has entered into a formal agreement with the U.S. Naval Air Warfare Center Weapons Division (NAWCWD), for the research and development of carbon nanostructures in advanced composite structures. The NAWCWD is the premier research and development center within the Naval Air Systems Command, conducting basic and applied research of advanced technologies related to
LITMUS Defense in Exclusive US Naval Air Warfare Center Cooperative Research Agr …
LITMUS, LLC, a leading global technology innovations company, today announces that its majority owned subsidiary, LITMUS Defense, LLC, has entered into a formal agreement with the U.S. Naval Air Warfare Center, Weapons Division (NAWCWD), for the research and development of carbon nanostructures in advanced rocket motors and warheads. The NAWCWD is the premier research and development center within the Naval Air Systems Command, conducting basic and applied research of advanced technologies
LITMUS and FDA Collaboration Leads to Global Food Safety Breakthrough
LITMUS, LLC, a leading global technology innovations company, announces today a breakthrough which will dramatically improve current testing methods to detect food borne pathogens such as Salmonella, Listeria, Campylobacter, and E.coli. This advancement in bacterial pathogen-testing technology provides growers, producers and processors quicker and more accurate results, thereby reducing the risk of contaminated foods reaching consumers. The new procedures are the result of a two-year collaboration between LITMUS
Appointment of LITMUS Defense CEO to Nanotechnology Board
LITMUS, LLC, a leading global technology innovations company, today announces that Bill Nevius, President and CEO of its wholly owned subsidiary, LITMUS Defense LLC, has been selected to join the Board of Directors of the Colorado Nanotechnology Alliance for 2007. The Alliance is a non-for-profit corporation established in 2006 to advance economic development in the State of Colorado, with a focus on the use of nanotechnology. The Alliance partners with

All 5 Releases


More Releases for LMD

Laser Microdissection (LMD) System Market Growth Factor with Regional Forecast, …
The Laser Microdissection (LMD) System Market report discusses in-depth the growth opportunities, challenges, growth drivers, restraints, threats, and demands of the market. Further, the research assesses the regional market as well as the global market to gather data on the scope of the Laser Microdissection (LMD) System market. The report also provides estimations and forecasts about the market segment and sub-segments exhibiting favorable growth in the upcoming timeline. The report
Laser Microdissection Market Report- Share by Application | Leica Microsystems, …
The Laser Microdissection Market research report has incorporated the total profile of the organizations with the capacity, creation, value, income, cost, gross, gross edge, deals volume, deals revenue, utilization, development rate, import, export, supply, future methodologies, and the mechanical advancements that they are making are likewise included inside Laser Microdissection Market report. Get FREE PDF Sample of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5270431 By Company - Leica Microsystems - Thermo Fisher Scientific - Carl Zeiss - Molecular
LMD 3D Printing Market Shares SWOT Analysis, Key Development Strategies and Fore …
The LMD 3D Printing Market report offers an in-depth assessment of market dynamics, the competitive landscape, segments, and regions in order to help readers to become familiar with the market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to plan effective strategies to gain success in the LMD 3D Printing market.  Importantly, it allows players to gain deep insights into
Global Laser Microdissection (LMD) System Industry Market Research Report from 2 …
The research report published by GLOBAL INFO RESEARCHis a comprehensive study of the global Laser Microdissection (LMD) Systemmarket. The subject matter experts and team of highly-skilled researchers have put in hours of work to collate an authentic research report on the global Laser Microdissection (LMD) Systemmarket. Analysts have studied the various products in the market and offered an unbiased opinion about the factors that likely to drive the market and
Global LMD 3D Printing Market to Witness a Pronounce Growth During 2024
LP INFORMATION offers a latest published report on LMD 3D Printing Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the LMD 3D Printing market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.
LMD 3D Printing Market 2019-2025|Major Players- TRUMPF, EFESTO, DMD3D, Optomec, …
The purpose of this research report titled “Global LMD 3D Printing Market Size, Status and Forecast 2019-2025” is to enlighten the readers about the global market during the period between 2019 and 2025. Market Research Hub (MRH) has diligently compiled this study to discuss various facets of the global LMD 3D Printing market together with the various players contributing to its future development. The inclusion of market dynamics, market size,